All In Biotech

Drug Trial Radar · NCT00422058

The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes

Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes: A 20-week Randomised, Double-blind, Placebo-controlled, Six Armed Parallel Group, Multi-centre, Multinational Trial With an Open Label Orlistat Comparator Arm and With an 84-week Extension Period

Last checked: Nov 20, 2026Latest source record: Nov 1, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 564 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

564

Actual

Start

Jan 10, 2007

Primary completion

Sep 13, 2007

Study completion Apr 30, 2009

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Jan 15, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is conducted in Europe. The purpose of the 20-week trial is to investigate the efficacy of liraglutide to induce body weight loss and the purpose of the extension is to evaluate the long term safety and tolerability of liraglutide. Trial has the following trial periods: A 20-week randomised, double-blind, placebo-controlled, six-armed parallel-group, multi-centre, multinational trial with an open label orlistat comparator arm followed by an 84 week extension period.

Conditions

  • Metabolism and Nutrition Disorder
  • Obesity

Interventions

  • liraglutideDrug

    Injected s.c. (under the skin) once daily

  • orlistatDrug

    120 mg capsule. Administered thrice daily

  • placeboDrug

    Injected s.c. (under the skin) once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change From Baseline in Body Weight at Week 20Time frame: Week 0, week 20

Locations

19 sites in 8 countries. Site status is shown where the registry gives one.

  • Novo Nordisk Investigational Site

    Edegem, Belgium

  • Novo Nordisk Investigational Site

    Prague, Czechia

  • Novo Nordisk Investigational Site

    Prague, Czechia

  • Novo Nordisk Investigational Site

    Århus C, Denmark

  • Novo Nordisk Investigational Site

    Frederiksberg C, Denmark

  • Novo Nordisk Investigational Site

    Hvidovre, Denmark

  • Novo Nordisk Investigational Site

    Helsinki, Finland

  • Novo Nordisk Investigational Site

    Kuopio, Finland

  • Novo Nordisk Investigational Site

    Oulu, Finland

  • Novo Nordisk Investigational Site

    Almere Stad, Netherlands

  • Novo Nordisk Investigational Site

    Barcelona, Spain

  • Novo Nordisk Investigational Site

    Madrid, Spain

  • Novo Nordisk Investigational Site

    Madrid, Spain

  • Novo Nordisk Investigational Site

    Pamplona, Spain

  • Novo Nordisk Investigational Site

    Malmö, Sweden

  • Novo Nordisk Investigational Site

    Stockholm, Sweden

  • Novo Nordisk Investigational Site

    Glasgow, United Kingdom

  • Novo Nordisk Investigational Site

    Luton, United Kingdom

  • Novo Nordisk Investigational Site

    Norwich, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.